Fig. 1 | Scientific Reports

Fig. 1

From: Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma

Fig. 1

Patient flowchart. Patients were assigned to receive Camrelizumab plus Paclitaxel/Paclitaxel for Injection (Albumin Bound) plus Cisplatin/Carboplatin plus Anlotinib (TCAC group), or Camrelizumab plus Paclitaxel/Paclitaxel for Injection (Albumin Bound) plus Cisplatin/Carboplatin (TCC group), or paclitaxe/Paclitaxel for Injection (Albumin Bound) plus Cisplatin/Carboplatin (TC group); treatments were administered every 3 weeks for four or six cycles, after which the patients received maintenance therapy with Camrelizumab plus Anlotinib in TCAC group, Camrelizumab in TCC group. The enrollment of the TC group was terminated in February 2022, so we only report the results of the TCAC and TCC groups here. There were 10 patients in the TCAC group and 2 patients in the TCC group who underwent radical surgery due to successful conversion therapy and were censored on the date of the surgical date. In addition, 2 patients in the TCC group were lost to follow-up. We conducted ORR, PFS, and OS analyses of the FAS population. This figure depicts the efficacy and safety populations analyzed in this study, with data current through the cutoff date of April 12, 2025.

Back to article page